罗氏公司通过其创新的扩展测序技术，推出了一类全新的下一代测序技术-动脉网

Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology

PHARMA FOCUS ASIA 等信源发布 2025-02-21 14:59



可切换为仅中文







Roche unveiled today its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing. SBX chemistry, combined with an innovative sensor module, offers ultra-rapid, high-throughput sequencing that is both flexible and scalable for a broad range of applications..

罗氏今天发布了其专有的、突破性的扩展测序（SBX）技术，开创了新一代测序的新类别。SBX化学结合创新的传感器模块，提供了超快速、高通量的测序，具有灵活性和可扩展性，适用于广泛的应用。

Next-generation sequencing provides detailed insights into genetics, genomics and cell biology. It has already improved our understanding of gene functions and interaction, and is critical to our ability to decode complex diseases such cancer, immune disorders, and neurodegenerative conditions, where hundreds or even thousands of genes impact disease progression..

下一代测序技术为遗传学、基因组学和细胞生物学提供了详细的见解。它已经加深了我们对基因功能和相互作用的理解，并且对我们解读复杂疾病（如癌症、免疫疾病和神经退行性疾病）的能力至关重要，在这些疾病中，数百甚至数千个基因影响着疾病的进展。

“The science behind SBX technology represents a significant breakthrough that addresses the limitations of existing sequencing solutions,” states Matt Sause, CEO of Roche Diagnostics. “By integrating and enhancing the two technologies, Roche's SBX has created a differentiated approach, offering unparalleled speed, efficiency and flexibility.

“SBX 技术背后的科学代表了一项重大突破，解决了现有测序解决方案的局限性，”罗氏诊断公司首席执行官 Matt Sause 表示。“通过整合和增强这两种技术，罗氏的 SBX 创造了一种差异化的方法，提供了无与伦比的速度、效率和灵活性。”

The speed and accuracy of SBX has the potential to revolutionise the use of sequencing in research and healthcare.”.

SBX的速度和准确性有潜力彻底改变测序在研究和医疗保健中的应用。

SBX is a novel sequencing approach which uses a sophisticated biochemical process to encode the sequence of a target nucleic acid molecule (DNA or RNA) into a measurable surrogate polymer called an Xpandomer. Xpandomers, which are fifty times longer than the original molecule, encode the sequence information into high signal-to-noise reporters, meaning they provide clear signals with minimal background noise.

SBX是一种新颖的测序方法，它利用复杂的生化过程将目标核酸分子（DNA或RNA）的序列编码到一种称为Xpandomer的可测量替代聚合物中。Xpandomer的长度是原始分子的50倍，能够将序列信息编码为高信噪比的报告分子，这意味着它们能提供清晰的信号且背景噪音极小。

This enables highly accurate single-molecule nanopore sequencing using a Complementary Metal Oxide Semiconductor (CMOS)-based sensor module with parallel processing capabilities, offering speed and flexibility beyond that of other sequencing technologies..

这使得使用基于互补金属氧化物半导体（CMOS）的传感器模块进行高度精确的单分子纳米孔测序成为可能，该模块具备并行处理能力，提供了超越其他测序技术的速度和灵活性。

“Solving the signal-to-noise challenge is a key efficiency driver for the technology. With this capability we can flexibly operate across a range of throughput scales using the same sequencing system, which provides a significant advantage to users,” said Mark Kokoris, Head of Roche's SBX Technology..

“解决信噪比挑战是该技术提高效率的关键。通过这一能力，我们可以使用同一台测序系统灵活地在多种通量规模下运行，这为用户提供了显著的优势，”罗氏SBX技术负责人马克·科科里斯表示。

The ability of SBX technology to provide ultra-rapid, high-throughput, flexible and scalable sequencing lends itself to a broad range of projects and applications. This technology will enable researchers to make significant discoveries that enhance our understanding of diseases and their treatment, with the potential to drive greater adoption in the clinical lab setting in the future..

SBX 技术能够提供超快速、高通量、灵活且可扩展的测序，这使其适用于广泛的项目和应用。该技术将使研究人员能够做出重大发现，从而加深我们对疾病及其治疗的理解，并有望在未来推动其在临床实验室环境中的更广泛应用。

About Sequencing by Expansion (SBX) technology

关于扩展测序（SBX）技术

Roche's groundbreaking next-generation sequencing technology is designed to overcome the limitations of traditional sequencing methods. As well as high accuracy, it also offers an unparalleled combination of flexibility and speed, making it a versatile tool for a wide range of genomic applications.

罗氏的突破性下一代测序技术旨在克服传统测序方法的局限性。除了高准确性，它还提供了无与伦比的灵活性和速度组合，使其成为广泛基因组应用的多功能工具。

One of the key benefits of SBX technology is its scalability. The chemistry is coupled with an advanced, high-throughput CMOS sensor module that enables ultra-rapid, real-time base calls and analysis. This module is designed to process numerous samples simultaneously, creating a highly scalable and flexible architecture for cost-efficient sequencing across different project sizes, from small-scale studies to large projects involving thousands of samples..

SBX 技术的主要优势之一是其可扩展性。该化学技术与先进的高通量 CMOS 传感器模块相结合，能够实现超快速的实时碱基识别和分析。该模块设计用于同时处理多个样本，构建了一个高度可扩展且灵活的架构，能够在不同规模的项目中实现经济高效的测序，从小型研究到涉及数千个样本的大型项目均可适用。

This versatility makes SBX technology suitable for a variety of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. As a result, it holds promise not only for research laboratories but also eventually for clinical settings where detailed genomic insights are crucial.

这种多功能性使得SBX技术适用于多种应用，包括全基因组测序、全外显子组测序和RNA测序。因此，它不仅在研究实验室中具有前景，最终在需要详细基因组洞察的临床环境中也展现出潜力。

With SBX technology, researchers can meet new and evolving research demands efficiently, paving the way for significant advances in our understanding of genetics and disease, ultimately contributing to better healthcare outcomes..

通过SBX技术，研究人员可以高效地满足新的和不断发展的研究需求，为深入了解遗传学和疾病铺平道路，最终有助于改善医疗保健结果。

SBX chemistry was invented by Mark Kokoris and Robert McRuer who co-founded Stratos Genomics. Stratos Genomics was acquired by Roche in 2020. To find out more about Roche’s novel SBX technology, click here.

SBX化学技术由马克·科科里斯和罗伯特·麦克鲁尔共同发明，他们同时也是Stratos Genomics的联合创始人。Stratos Genomics于2020年被罗氏收购。欲了解罗氏创新的SBX技术，请点击这里。

About Roche’s Sequencing Portfolio

关于罗氏的测序产品组合

Roche has been committed to providing next-generation sequencing library prep solutions and application support for sequencing for several years. Today, next-generation sequencing solutions from Roche play an important role in the sequencing ecosystem. Our KAPA sample preparation products offer high-performance DNA, RNA library prep and target enrichment solutions for a variety of applications.

罗氏多年来一直致力于提供下一代测序文库制备解决方案和测序应用支持。如今，罗氏的下一代测序解决方案在测序生态系统中发挥着重要作用。我们的KAPA样品制备产品为多种应用提供了高性能的DNA、RNA文库制备和目标富集解决方案。

Additionally, we offer the AVENIO Edge system that provides a true walk-away automated solution for many of our KAPA kits. This system does not require advanced programming skills and comes with ready-to-use kits and protocols. Our AVENIO assays offer robust solutions for oncology, including the recent approval of the AVENIO Tumor Tissue CGP Automated Kit, a collaboration between Roche and Foundation Medicine, two leaders in oncology..

此外，我们还提供AVENIO Edge系统，为我们的许多KAPA试剂盒提供了真正的全自动化解决方案。该系统不需要高级编程技能，并配有即用型试剂盒和协议。我们的AVENIO检测方法为肿瘤学提供了强大的解决方案，其中包括最近获批的AVENIO肿瘤组织CGP自动化试剂盒，这是罗氏与Foundation Medicine两家肿瘤学领导者合作的成果。

About Roche

关于罗氏

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world.

罗氏公司成立于1896年，位于瑞士巴塞尔，是最早生产品牌药品的工业制造商之一。如今，罗氏已发展成为全球最大的生物技术公司，同时也是体外诊断领域的全球领导者。公司致力于科学卓越，通过发现和开发药物及诊断工具，改善并拯救全球人类的生命。

We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice..

我们是个性化医疗的先驱，希望进一步改变医疗服务的提供方式，以产生更大的影响。为了给每个人提供最好的护理，我们与许多利益相关者合作，将我们在诊断和制药领域的优势与临床实践中的数据洞察相结合。

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045..

125 多年来，可持续发展一直是罗氏业务的重要组成部分。作为一家以科学为驱动的公司，我们对社会的最大贡献在于开发创新药物和诊断技术，帮助人们过上更健康的生活。罗氏致力于基于科学的目标倡议和可持续市场倡议，到 2045 年实现净零排放。

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

美国的基因泰克公司是罗氏集团的全资成员。罗氏是日本中外制药公司的控股股东。

For more information, please visit www.roche.com.

欲了解更多信息，请访问 www.roche.com。

All trademarks used or mentioned in this release are protected by law.

本发布中使用或提到的所有商标均受法律保护。

Roche Global Media Relations

罗氏全球媒体关系

Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

电话：+41 61 688 8888 / 电子邮件：media.relations@roche.com

Hans Trees, PhD